Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 23, 2020
Daily News
January 23, 2020
- Generic Industry Will Need Strategies Beyond Core Business for “Post-80%” Era: JGA President
January 23, 2020
- Takeda to Liquidate Shire’s Irish Holding Firm
January 23, 2020
- Chuikyo OKs New Drug Pricing Rules for 2020 Reform
January 23, 2020
- Revoke Conditional OK for Stemirac: Drug Damage Watchdog
January 23, 2020
- Kissei’s Spinocerebellar Degeneration Drug Fails to Meet Primary Goal in PIII, but Shows Positive Results in Severe Patients
January 23, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…